Tags

Type your tag names separated by a space and hit enter

[Nonalcoholic steatohepatitis--a "new" hepatic disease].
Ugeskr Laeger. 2003 Mar 10; 165(11):1115-8.UL

Abstract

Non-alcoholic fatty liver disease (NAFLD) is one of the most common hepatic disorders in the Western world. Non-alcoholic steatohepatitis (NASH) may occur in a subset of NAFLD patients and is an increasingly recognised clinicopathologial hepatic disorder. NASH may have significant impact on the healthcare system as it is associated with the metabolic syndrome comprising insulin resistance, obesity, hypertension, and type 2 diabetes mellitus. NASH can progress to liver fibrosis, cirrhosis and chronic hepatic failure and eventually to the need for a liver transplantation. The present review deals with the epidemiological features of NASH, describes a two-step pathogenesis with hepatic lipid accumulation (NAFLD) followed by the development of steatohepatitis (NASH). A strategy for establishing a diagnosis of NASH is presented including the indication for liver biopsy. The treatment of NASH may comprise different modalities from diet, weight loss, and exercise to pharmacological treatment to improve insulin resistance and drugs with antioxidant effects.

Authors+Show Affiliations

Medicinsk Afdeling V, Arhus Kommunehospital, DK-8000 Arhus C. henning.gronbaek@dadlnet.dkNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

dan

PubMed ID

12677985

Citation

Grønbaek, Henning, et al. "[Nonalcoholic Steatohepatitis--a "new" Hepatic Disease]." Ugeskrift for Laeger, vol. 165, no. 11, 2003, pp. 1115-8.
Grønbaek H, Eivindson MV, Hamilton-Dutoit S, et al. [Nonalcoholic steatohepatitis--a "new" hepatic disease]. Ugeskr Laeger. 2003;165(11):1115-8.
Grønbaek, H., Eivindson, M. V., Hamilton-Dutoit, S., & Vilstrup, H. (2003). [Nonalcoholic steatohepatitis--a "new" hepatic disease]. Ugeskrift for Laeger, 165(11), 1115-8.
Grønbaek H, et al. [Nonalcoholic Steatohepatitis--a "new" Hepatic Disease]. Ugeskr Laeger. 2003 Mar 10;165(11):1115-8. PubMed PMID: 12677985.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Nonalcoholic steatohepatitis--a "new" hepatic disease]. AU - Grønbaek,Henning, AU - Eivindson,Martin V, AU - Hamilton-Dutoit,Stephen, AU - Vilstrup,Hendrik, PY - 2003/4/8/pubmed PY - 2003/5/20/medline PY - 2003/4/8/entrez SP - 1115 EP - 8 JF - Ugeskrift for laeger JO - Ugeskr Laeger VL - 165 IS - 11 N2 - Non-alcoholic fatty liver disease (NAFLD) is one of the most common hepatic disorders in the Western world. Non-alcoholic steatohepatitis (NASH) may occur in a subset of NAFLD patients and is an increasingly recognised clinicopathologial hepatic disorder. NASH may have significant impact on the healthcare system as it is associated with the metabolic syndrome comprising insulin resistance, obesity, hypertension, and type 2 diabetes mellitus. NASH can progress to liver fibrosis, cirrhosis and chronic hepatic failure and eventually to the need for a liver transplantation. The present review deals with the epidemiological features of NASH, describes a two-step pathogenesis with hepatic lipid accumulation (NAFLD) followed by the development of steatohepatitis (NASH). A strategy for establishing a diagnosis of NASH is presented including the indication for liver biopsy. The treatment of NASH may comprise different modalities from diet, weight loss, and exercise to pharmacological treatment to improve insulin resistance and drugs with antioxidant effects. SN - 0041-5782 UR - https://www.unboundmedicine.com/medline/citation/12677985/[Nonalcoholic_steatohepatitis__a_"new"_hepatic_disease]_ L2 - https://medlineplus.gov/hepatitis.html DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.